Skip to main content

Possis Medical

( POSS) was rising 11% after an analyst at Stanford Research upgraded the company's shares to buy from sell. The medical-device company's shares were adding $1.26 to $12.86.


( VTIV) gained 16% Monday after the drug marketer reported strong second-quarter earnings and announced an acquisition. On a continuing operations basis, Ventiv earned $9 million, or 32 cents a share, in the quarter, beating estimates by 7 cents. Revenue of $132 million was also above forecasts. Ventiv, which guided full-year earnings higher, said it has acquired Pharmaceutical Resource, a privately held drug services company. The stock was recently up $3.41 to $24.29.



rose 14% Monday after agreeing to be acquired by

Quest Diagnostics

(DGX) - Get Quest Diagnostics Incorporated Report

in a deal worth $934 million. Quest will pay $43.90 in cash for each LabOne share. In recent trading, LabOne was up $5.16 to $42.80. Quest was adding 4% to $49.25.

GTC Biotherapeutics

Scroll to Continue

TheStreet Recommends

( GTCB) was dropping 17% after the company agreed to sell about 4.57 million shares to investors at $1.75 each. The investors will also receive five-year warrants to buy about 1.8 million additional shares at an exercise price of $2.68 a share. The company, a developer of therapeutic proteins, saw its shares lose 40 cents to $1.93.

Advanced Life Sciences Holdings


was down nearly 16% Monday following a post-IPO runup in its shares Friday. Last week, the biopharmaceutical company priced an initial public offering of 6.4 million shares at $5 each. Recently, the stock was down 95 cents to $5.05 from Friday's close at $6.

Shares of

ISTA Pharmaceuticals

( ISTA), a developer of products for eye conditions, were falling almost 10% after an analyst downgraded the company's stock rating. RBC Capital Markets lowered its rating on ISTA to sector perform from outperform. The stock was down 88 cents to $8.

SciClone Pharmaceuticals


slid 12% after the company posted its latest quarterly results and offered guidance. For the second quarter, revenue from the sale of Zadaxin reached $6.9 million, up from $5.6 million a year ago. The biopharmaceutical company lost $1.9 million, or 4 cents a share, in the quarter.

For the full year, SciClone raised its Zadaxin sales estimate to between $27 million and $28 million from between $25 million and $26 million. SciClone cut its guidance for research and development expenses to between $14 million and $15 million. Additionally, the company narrowed its estimated loss. Shares of SciClone were down 85 cents to $6.20.